Condition: Pancreatic Cancer · Proton Therapy · Sponsor: EBG MedAustron GmbH
This is an interventional, single arm, open-label, feasibility trial with gemcitabine and nab-paclitaxel, followed by concomitant proton therapy and capecitabine, followed by re-evaluation and surgery (when feasible) for patients with borderline resectable pancreatic cancer.
This description comes directly from the study's public registry record.
Piero Fossati, M.D. · +43 664 80878 · piero.fossati@medaustron.at
Always discuss trial participation with your own doctor first.
| EBG MedAustron GmbH | Wiener Neustadt, Lower Austria, Austria | Recruiting |
| Department of Surgery, LK Wiener Neustadt | Wiener Neustadt, Austria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04894643